Trial Profile
A study to evaluate miRNAs associated with therapeutic response in metastatic renal cell carcinoma patients treated with sunitinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 23 Mar 2016 New trial record